Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep-Oct;19(5):533-7.
doi: 10.1016/j.bjid.2015.04.003. Epub 2015 May 18.

Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection

Raul Carlos Wahle  1 , Renata Mello Perez  2 , Patrícia Fucuta Pereira  3 , Elze Maria Gomes Oliveira  3 , Christini Takemi Emori  3 , Silvia Naomi de Oliveira Uehara  3 , Ivonete Sandra de Souza Silva  3 , Antônio Eduardo Benedito Silva  3 , Maria Lucia Gomes Ferraz  3
Affiliations

Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection

Raul Carlos Wahle et al. Braz J Infect Dis. 2015 Sep-Oct.

Abstract

In coinfected HBV/HCV patients, HBV replication is usually suppressed by HCV over the time. No study to date has evaluated the HBV viremia in long-term follow-up after HCV treatment in hemodialysis patients with HBV/HCV coinfection. This study aimed to assess the evolution of HBV viremia after HCV treatment in this special population. Ten hemodialysis patients with HBV/HCV coinfection with dominant HCV infection (HBV lower than 2000 IU/mL) and significant fibrosis were treated with interferon-alpha 3 MU 3×/week for 12 months and could be followed for at least 36 months after HCV treatment. Six cases of HBV reactivation (60%) during follow-up were observed and 5/6 had been successfully treated for HCV. Patients with HBV reactivation received anti-HBV therapy. Our preliminary findings indicate that treatment of hepatitis C in HBV/HCV coinfected hemodialysis patients may favor HBV reactivation. Thus, continued monitoring of HBV viremia must be recommended and prompt anti-HBV therapy should be implemented.

Keywords: Coinfection HBV/HCV; Hemodialysis; Reactivation HBV.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Profiles of serum HCV-RNA and HBV-DNA in six patients with HBV reactivation during follow-up after HCV treatment in months. HCV-RNA and HBV-DNA levels are expressed as log10 IU/mL and lower limit of detection of both tests are 50 IU/mL. Abbreviation: EOT, end of hepatitis C treatment; LAM, lamivudine; ADV, adefovir.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rapti I.N., Hadziyannis S.J. Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol Hepatol. 2011;5:323–339. - PubMed
    1. Fabrizi F., Messa P., Basile C., et al. Hepatic disorders in chronic kidney disease. Nat Rev Nephrol. 2010;6:395–403. - PubMed
    1. Fabrizi F., Martin P., Dixit V.F., et al. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5:2913–2921. - PubMed
    1. Raimondo G., Brunetto M.R., Pontisso P., et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus co-infected patients. Hepatology. 2006;43:100–107. - PubMed
    1. Yu M.L., Lee C.M., Chen C.L., et al. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology. 2013;57:2135–2142. - PubMed

MeSH terms